SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of report:
June 17, 2003
Date of earliest event reported:
June 17, 2003
PFIZER INC.
---------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 001-03619 13-5315170
--------------------------------------------------------------------------------
(State or other jurisdiction (Commission File (I.R.S. Employer
of incorporation) Number) Identification No.)
235 East 42nd Street, New York, New York 10017
--------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code
(212) 573-2323
--------------------------------------------------------------------------------
(Former name or former address, if changed since last report.)
Item 12. Results of Operations and Financial Condition
On June 17, 2003, Pfizer Inc. ("Pfizer") will hold a meeting with securities
analysts in New York, New York. Pfizer will present certain financial
information reflecting its merger with Pharmacia Corporation, completed on April
16, 2003. Pfizer will report, among other things, that in relation to pro-forma
2002 Pfizer/Pharmacia combined revenue of $45 billion, 2004 revenue of $54
billion represents approximately 10% compound annual revenue growth. Adjusted
diluted earnings per share of $2.13 in 2004 represents 16% compound growth from
2002. A copy of a visual aid including this information is attached to this
Report as Exhibits 99 and is incorporated by reference.
A reconciliation of Pfizer's revenues for the year ended December 31, 2002 as
reported in its 2002 Annual Report to Shareholders to pro-forma 2002
Pfizer/Pharmacia combined revenue for the year ended December 31, 2002 is as
follows:
($ in Millions) Year Ended December 31, 2002
Pfizer reported revenues $32,373
Pharmacia reported revenues 13,993
Proforma adjustment (*) (1,368)
-------
Pfizer/Pharmacia combined revenue $44,998
* To eliminate transactions between Pfizer and Pharmacia which occurred under
the Celebrex and Bextra marketing agreements.
Pfizer will file pro-forma financial statements relating to the acquisition of
Pharmacia, as required pursuant to Item 7(b) of Report on Form 8-K, on or before
June 30, 2003. The announcement of the acquisition of Pharmacia was reported on
Form 8-K filed on April 16, 2003.
Item 7(c). Financial Statements Exhibits
Exhibit Description
------- -----------
99 Visual aid used at securities analyst presentation by Pfizer Inc.
2
Signature
Under the requirements of the Securities Exchange Act of 1934, the registrant
has caused this report to be signed on its behalf by the authorized undersigned.
PFIZER INC.
--------------------------------------
(Registrant)
Date: June 17, 2003
/s/ Margaret M. Foran
--------------------------------------
Name: Margaret M. Foran
Title: Vice President - Corporate
Governance and Secretary
EXHIBIT INDEX
Exhibit Description
------- -----------
99 Visual aid used at securities analyst presentation by Pfizer Inc.